DK1087993T3 - Fas-peptider og antistoffer til at modulere apoptose - Google Patents
Fas-peptider og antistoffer til at modulere apoptoseInfo
- Publication number
- DK1087993T3 DK1087993T3 DK99931070T DK99931070T DK1087993T3 DK 1087993 T3 DK1087993 T3 DK 1087993T3 DK 99931070 T DK99931070 T DK 99931070T DK 99931070 T DK99931070 T DK 99931070T DK 1087993 T3 DK1087993 T3 DK 1087993T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- peptides
- fas
- phas
- modulate apoptosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9813194.9A GB9813194D0 (en) | 1998-06-18 | 1998-06-18 | Methods and means for modulating apoptosis |
GBGB9905793.7A GB9905793D0 (en) | 1998-06-18 | 1999-03-12 | Methods and means for modulating apoptosis |
PCT/EP1999/004105 WO1999065935A2 (en) | 1998-06-18 | 1999-06-15 | Fas peptides and antibodies for modulating apoptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1087993T3 true DK1087993T3 (da) | 2008-07-14 |
Family
ID=26313898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99931070T DK1087993T3 (da) | 1998-06-18 | 1999-06-15 | Fas-peptider og antistoffer til at modulere apoptose |
Country Status (9)
Country | Link |
---|---|
US (1) | US6846637B1 (da) |
EP (1) | EP1087993B1 (da) |
AT (1) | ATE391136T1 (da) |
AU (1) | AU4772299A (da) |
DE (1) | DE69938451T2 (da) |
DK (1) | DK1087993T3 (da) |
ES (1) | ES2306515T3 (da) |
PT (1) | PT1087993E (da) |
WO (1) | WO1999065935A2 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2490542C (en) | 2002-05-23 | 2013-07-16 | Mark I. Greene | Fas peptide mimetics and uses thereof |
AU2003249533A1 (en) | 2002-07-04 | 2004-01-23 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
DE10311248A1 (de) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
WO2004094647A2 (en) * | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
US20070244304A1 (en) * | 2003-11-12 | 2007-10-18 | Oncomab Gmbh | Methods of Identifying Neoplasm-Specific Antibodies and Uses Thereof |
EP1531162A1 (en) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
US7759077B2 (en) | 2005-08-02 | 2010-07-20 | Shariat Shahrokh F | Soluble fas urinary marker for the detection of bladder transitional cell carcinoma |
JP5558828B2 (ja) | 2006-12-28 | 2014-07-23 | ドイチェス クレープスフォルシュングスツェントルム | インビボでの神経膠芽腫細胞の浸潤を阻害するcd95活性の中和 |
EP2318441A2 (en) * | 2008-07-14 | 2011-05-11 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
KR20110128923A (ko) * | 2009-03-12 | 2011-11-30 | 이메드 아베 | 인간 fas에 대한 인간 항체 및 그의 용도 |
AU2013291981B2 (en) | 2012-07-18 | 2017-05-04 | Apogenix Ag | Inhibitors of the CD95 signaling pathway for treatment of MDS |
US20160115237A1 (en) | 2013-05-24 | 2016-04-28 | The University Of British Columbia | Cell senescence markers as diagnostic and therapeutic targets |
EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
EP3131922B1 (en) * | 2014-04-17 | 2020-05-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polypeptides and uses thereof for reducing cd95-mediated cell motility |
EP3076179A1 (en) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnosis and treatment of low grade gliomas |
EP3454884B1 (en) | 2016-05-10 | 2023-07-12 | Sorbonne Université | Agents that activate cd47 and their use in the treatment of inflammation |
WO2020205662A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Inc. | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
JP2023504042A (ja) | 2019-11-27 | 2023-02-01 | ミスト セラピューティクス リミテッド ライアビリティ カンパニー | 調節物質を使用した腫瘍反応性t細胞組成物の生成方法 |
WO2021174208A1 (en) | 2020-02-27 | 2021-09-02 | Myst Therapeutics, Llc | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0511202B1 (en) | 1990-01-19 | 1994-06-01 | German Cancer Research Center | A cell surface antigen associated with cellular apoptosis |
CA2067031C (en) | 1991-04-26 | 2003-02-18 | Shigekazu Nagata | Dna coding for human cell surface antigen |
US5891434A (en) | 1991-06-17 | 1999-04-06 | Centocor, Inc. | Monoclonal antibodies to the APO-1 antigen |
AU705114B2 (en) | 1993-10-14 | 1999-05-13 | Immunex Corporation | Fas antagonists and uses thereof |
US5830469A (en) | 1993-10-14 | 1998-11-03 | Immunex Corporation | Fas antagonists and uses thereof |
US5663070A (en) | 1993-11-15 | 1997-09-02 | Lxr Biotechnology Inc. | Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM |
CA2158822C (en) | 1994-09-27 | 2008-12-23 | Kusuki Nishioka | Therapeutic agent for rheumatic disease |
JPH08157500A (ja) * | 1994-12-08 | 1996-06-18 | Oriental Yeast Co Ltd | Fas抗原の定量法 |
WO1997012632A1 (en) | 1995-10-05 | 1997-04-10 | Tkb Associates Limited Partnership | Methods for treatment of diseases associated with a deficiency of fas ligand activity |
DE19544332C2 (de) * | 1995-11-28 | 1999-07-08 | Deutsches Krebsforsch | Verfahren zum Nachweis der Expression von CD95 Ligand in Zellen |
JP3663243B2 (ja) * | 1995-12-14 | 2005-06-22 | 株式会社医学生物学研究所 | Fas抗原の免疫学的測定法及び測定用キット |
NO971448L (no) | 1996-04-01 | 1997-10-02 | Sankyo Co | Rekombinante anti-Fas-antistoffer og DNA for disse |
US5912168A (en) * | 1996-08-30 | 1999-06-15 | Genesis Research & Development Corporation Limited | CD95 regulatory gene sequences |
IL123756A0 (en) | 1997-03-21 | 1998-10-30 | Sankyo Co | Humanized anti-human FAS antibody |
IL123888A0 (en) | 1997-04-01 | 1998-10-30 | Sankyo Co | Anti-fas antibodies |
AU757961B2 (en) | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
PL352159A1 (en) | 1999-05-24 | 2003-07-28 | Sankyo Co | Pharmaceutical compositions containing antibody against the fas |
-
1999
- 1999-06-15 ES ES99931070T patent/ES2306515T3/es not_active Expired - Lifetime
- 1999-06-15 DE DE69938451T patent/DE69938451T2/de not_active Expired - Lifetime
- 1999-06-15 PT PT99931070T patent/PT1087993E/pt unknown
- 1999-06-15 US US09/719,646 patent/US6846637B1/en not_active Expired - Fee Related
- 1999-06-15 DK DK99931070T patent/DK1087993T3/da active
- 1999-06-15 EP EP99931070A patent/EP1087993B1/en not_active Revoked
- 1999-06-15 WO PCT/EP1999/004105 patent/WO1999065935A2/en active IP Right Grant
- 1999-06-15 AT AT99931070T patent/ATE391136T1/de active
- 1999-06-15 AU AU47722/99A patent/AU4772299A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69938451D1 (de) | 2008-05-15 |
AU4772299A (en) | 2000-01-05 |
EP1087993A1 (en) | 2001-04-04 |
WO1999065935A2 (en) | 1999-12-23 |
US6846637B1 (en) | 2005-01-25 |
WO1999065935A3 (en) | 2003-04-17 |
ATE391136T1 (de) | 2008-04-15 |
PT1087993E (pt) | 2008-07-04 |
ES2306515T3 (es) | 2008-11-01 |
DE69938451T2 (de) | 2009-04-09 |
EP1087993B1 (en) | 2008-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1087993T3 (da) | Fas-peptider og antistoffer til at modulere apoptose | |
HUP0400951A2 (hu) | Egy tumornekrózis faktorral rokon apoptózis indikáló ligandum receptorára specifikus antitest és alkalmazásai | |
ATE227739T1 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
WO2003082919A3 (en) | Ox40r binding agents | |
BR9809387A (pt) | Anticorpos anti-vegf | |
DE69840966D1 (de) | Homolog NL6 des Tie Rezeptor Tyrosinekinase Liganden | |
EA200400312A1 (ru) | АНТАГОНИСТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFSF13b ЧЕЛОВЕКА | |
DK1606317T3 (da) | Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation | |
PT2305715T (pt) | Anticorpo monoclonal para a proteína de ligação a osteoprotegerina | |
UA96122C2 (ru) | Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение | |
ATE382053T1 (de) | System zur antikörperexpression und- synthese | |
PL373531A1 (en) | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof | |
WO2004048544A3 (en) | Ca ix-specific inhibitors | |
TW200635946A (en) | Binding proteins specific for human matriptase | |
WO2000001813A3 (en) | Peptide inhibitors of androgen-independent activation of androgen receptor | |
WO2002065134A3 (en) | Modulators of p53-p300 interactions and screening methods therefor | |
EP1517144A3 (en) | Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor | |
HUP0402496A2 (hu) | Módosított polipeptidek | |
SE0000675D0 (sv) | Monoclonal antibodies | |
BR0308401A (pt) | Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento. | |
WO2004012673A3 (en) | Methods and reagents relating to inflammation and apoptosis | |
DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
WO2002092765A3 (en) | Novel telomerase inhibitors and uses therefor | |
ATE240349T1 (de) | Peptide zur inhibierung von hpv e6-proteinen | |
CN100551930C (zh) | 调节caspase活化的肽 |